Skip to main content

Research Repository

Advanced Search

The RNA revolution and cancer (2024)
Journal Article
Dlamini, Z., Ladomery, M., & Kahraman, A. (2024). The RNA revolution and cancer. Frontiers in Endocrinology, 15, Article 1422599. https://doi.org/10.3389/fendo.2024.1422599

RNA biology has revolutionized cancer understanding and treatment, especially in endocrine-related malignancies. This editorial highlights RNA's crucial role in cancer progression, emphasizing its influence on tumor heterogeneity and behavior. Proces... Read More about The RNA revolution and cancer.

Anticancer effects of the Novel Pyrazolyl-Urea GeGe-3 (2024)
Journal Article
Williams, A., Cooper, E., Clark, B., Perry, L., Ponassi, M., Iervasi, E., …Ladomery, M. (2024). Anticancer effects of the Novel Pyrazolyl-Urea GeGe-3. International Journal of Molecular Sciences, 25(10), Article 5380. https://doi.org/10.3390/ijms25105380

In a screen of over 200 novel pyrazole compounds, ethyl 1-(2-hydroxypentyl)-5-(3-(3- (trifluoromethyl) phenyl)ureido)-1H-pyrazole-4-carboxylate (named GeGe-3) has emerged as a potential anticancer compound. GeGe-3 displays potent anti-angiogenic pr... Read More about Anticancer effects of the Novel Pyrazolyl-Urea GeGe-3.

Going circular: history, present, and future of circRNAs in cancer. (2023)
Journal Article
Pisignano, G., Michael, D. C., Pirlog, R., Visal, T. H., Ladomery, M., & Calin, G. A. (2023). Going circular: history, present, and future of circRNAs in cancer. Oncogene, 42, 2783–2800. https://doi.org/10.1038/s41388-023-02780-w

To date, thousands of highly abundant and conserved single-stranded RNA molecules shaped into ring structures (circRNAs) have been identified. CircRNAs are multifunctional molecules that have been shown to regulate gene expression transcriptionally a... Read More about Going circular: history, present, and future of circRNAs in cancer..

CDC2-like (CLK) protein kinase inhibition as a novel targeted therapeutic strategy in prostate cancer (2021)
Journal Article
Uzor, S., Porazinski, S., Li, L., Clark, B., Ajiro, M., Iida, K., …Ladomery, M. (2021). CDC2-like (CLK) protein kinase inhibition as a novel targeted therapeutic strategy in prostate cancer. Scientific Reports, 11(1), Article 7963. https://doi.org/10.1038/s41598-021-86908-6

Dysregulation of alternative splicing is a feature of cancer, both in aetiology and progression. It occurs because of mutations in splice sites or sites that regulate splicing, or because of the altered expression and activity of splice factors and o... Read More about CDC2-like (CLK) protein kinase inhibition as a novel targeted therapeutic strategy in prostate cancer.

Epigenenetic regulation of alternative splicing: How lncRNAs tailor the message (2021)
Journal Article
Pisignano, G., & Ladomery, M. (2021). Epigenenetic regulation of alternative splicing: How lncRNAs tailor the message. Non-Coding RNA, 7(1), Article 21. https://doi.org/10.3390/ncrna7010021

Alternative splicing is a highly fine-tuned regulated process and one of the main drivers of proteomic diversity across eukaryotes. The vast majority of human multi-exon genes is alternatively spliced in a cell type-and tissue-specific manner, and de... Read More about Epigenenetic regulation of alternative splicing: How lncRNAs tailor the message.

WT1 activates transcription of the splice factor kinase SRPK1 gene in PC3 and K562 cancer cells in the absence of corepressor BASP1 (2020)
Journal Article
Belali, T., Wodi, C., Clark, B., Cheung, M. K., Craig, T. J., Wheway, G., …Ladomery, M. (2020). WT1 activates transcription of the splice factor kinase SRPK1 gene in PC3 and K562 cancer cells in the absence of corepressor BASP1. BBA - Gene Regulatory Mechanisms, 1863(12), Article 194642. https://doi.org/10.1016/j.bbagrm.2020.194642

Dysregulated alternative splicing plays a prominent role in all hallmarks of cancer. The splice factor kinase SRPK1 drives the activity of oncogenic splice factors such as SRSF1. SRSF1 in turn promotes the expression of splice isoforms that favour tu... Read More about WT1 activates transcription of the splice factor kinase SRPK1 gene in PC3 and K562 cancer cells in the absence of corepressor BASP1.

Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer (2020)
Journal Article
Li, L., Hobson, L., Perry, L., Clark, B., Heavey, S., Haider, A., …Ladomery, M. (2020). Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer. British Journal of Cancer, 123, 1024-1032. https://doi.org/10.1038/s41416-020-0951-2

Background: The ERG oncogene, a member of the ETS family of transcription factor encoding genes, is a genetic driver of prostate cancer. It is activated through a fusion with the androgen-responsive TMPRSS2 promoter in 50% of cases. There is therefor... Read More about Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer.

APC and AXIN2 are promising biomarker candidates for the early detection of adenomas and hyperplastic polyps (2020)
Journal Article
Almond, S., Anaraki, F., Young, C., Ashrafian Bonab, M., Asadzadeh-Aghdaei, H., Rezvani, H., …Ladomery, M. (2020). APC and AXIN2 are promising biomarker candidates for the early detection of adenomas and hyperplastic polyps. Cancer Informatics, 19, 1-8. https://doi.org/10.1177/1176935120972383

Aberrant activation of the WNT/CTNNB1 pathway is notorious in colorectal cancer (CRC). Here, we demonstrate that the expression of specific and crucial WNT signaling pathway genes is linked to disease progression in colonic adenomatous (AP) and hyper... Read More about APC and AXIN2 are promising biomarker candidates for the early detection of adenomas and hyperplastic polyps.

Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment (2019)
Journal Article
Koschorke, A., Faraci, S., Giani, D., Chiodoni, C., Iorio, E., Canese, R., …Pupa, S. M. (2019). Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment. Cellular Oncology, 42(6), 815-828. https://doi.org/10.1007/s13402-019-00464-w

© 2019, International Society for Cellular Oncology. Purpose: Isothiocyanates elicit anticancer effects by targeting cancer stem cells (CSCs). Here, we tested the antitumor activity of phenethyl-isothiocyanate (PEITC), either alone or in combination... Read More about Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment.